Bioequivalence study of Lansoprazole 30 mg capsule
Not Applicable
Recruiting
- Conditions
- This study is performed on healthy volunteers..
- Registration Number
- IRCT20200623047902N40
- Lead Sponsor
- Actover Co
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 24
Inclusion Criteria
General Health (Liver, Heart, and Kidney)
Body Mass Index (18-28)
Informed consent
Age (18-55 years old)
Exclusion Criteria
Smoking
History of cardiovascular disease
History of liver and kidney disease
Alcoholism and Narcoticism
History of allergy to lansoprazole
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What are the molecular mechanisms of lansoprazole in gastric acid suppression and PPI efficacy?
How does Actover Co's lansoprazole compare to originator in CYP2C19 metabolizer subtypes?
What are the primary pharmacokinetic endpoints in IRCT20200623047902N40 bioequivalence trial?
Which adverse events are associated with lansoprazole 30 mg in healthy volunteers?
What are the current PPI alternatives for H. pylori eradication and GERD management in clinical practice?